id: finasteride_use_bph_to_psychiatric_disorders
name: Finasteride Use for Benign Prostatic Hyperplasia â†’ Psychiatric Disorders
from_node:
  node_id: finasteride_use_bph
  node_name: Finasteride Use for Benign Prostatic Hyperplasia
to_node:
  node_id: psychiatric_disorders
  node_name: Psychiatric Disorders
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Finasteride 5mg daily inhibits 5-alpha reductase, reducing DHT for prostate
  symptom management'
- 'Step 2: Altered androgen metabolism affects neurosteroid synthesis in older adults'
- 'Step 3: Age-related differences in neuroplasticity and receptor sensitivity may
  buffer psychiatric effects'
- 'Step 4: Overall psychiatric disorder incidence remains similar to age-matched controls
  despite drug exposure'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'Anna Lyakhovitsky et al. 2024. "The risk of psychiatric disorders
    in finasteride users with benign prostatic hyperplasia and androgenetic alopecia:
    A population-based case-control study.." *The Australasian journal of dermatology*.
    https://doi.org/10.1111/ajd.14359'
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:05.553436'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: age
  direction: weakens
  strength: strong
  description: BPH patients had mean age 61.5 years versus AGA patients at 31.4 years;
    older age associated with no significant psychiatric risk increase
- name: finasteride_dose
  direction: weakens
  strength: weak
  description: BPH patients received 5mg daily versus 1mg for AGA, but showed lower
    psychiatric risk despite higher dose
